Clinical Trial

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Study acronym: TIRACAN
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-01; most recent amendment 2025-03-28.
Status change: Not Yet Recruiting → Recruiting 2024-01-09
Trial Details
NCT Number NCT05483400
Lead Sponsor University Medical Center Groningen
Conditions Head and Neck Neoplasms, MSI-H Cancer, Melanoma
Enrollment 97 participants
Start Date 2023-10-18
Primary Completion 2025-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2025-03-30